Interleukin-2 therapy of Langerhans cell histiocytosis.
A 20-month-old girl was diagnosed with Langerhans cell histiocytosis on the basis of a seborrheic skin rash, multiple punched out bony lesions, and skin biopsy findings. Combination therapy including alpha-interferon, vincristine, vindesine, cyclophosphamide, etoposide, cisplatin, betamethasone, THP-adriamycin, cytarabine and methotrexate was ineffective. Because cyclophosphamide enhanced lesion growth within the skull, we administered an intravenous infusion of interleukin-2 with remarkable efficacy. The reduction in lesion size with interleukin-2 treatment paralleled the increase in the percentage of CD16-positive natural killer cells in the peripheral blood.
Hirose
M
M
Department of Pediatrics, Tokushima University School of Medicine, Japan.
Saito
S
S
Yoshimoto
T
T
Kuroda
Y
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016516:CD4-CD8 Ratio; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D017452:Receptors, IgG / Q000032:analysis; D012074:Remission Induction; D014751:Vindesine / Q000008:administration & dosage
D007376:Interleukin-2; D017452:Receptors, IgG; D005047:Etoposide; D011239:Prednisolone; D014751:Vindesine